TG Therapeutics | TGTX - Operating Profit



TG Therapeutics reported $34.84M in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
AbbVie USD 5.72B 1.98B Jun/2025
Alaunos Therapeutics USD -755000 395K Dec/2024
Amgen USD 2.66B 1.37B Jun/2025
Ardelyx USD -14400000 22.52M Jun/2025
Arrowhead Research USD -165550000 546.75M Jun/2025
Bayer EUR 13M 2.31B Jun/2025
Biogen USD 851.8M 540.6M Jun/2025
Corcept Therapeutics USD 26.67M 23.26M Jun/2025
Dynavax Technologies USD 10.86M 34.49M Jun/2025
Gilead Sciences USD 2.7B 467M Jun/2025
J&J USD 6.94B 6.69B Jun/2025
Novartis USD 4.86B 201M Jun/2025
PTC Therapeutics USD -34858000 1.01B Jun/2025
Regeneron Pharmaceuticals USD 1.08B 487.8M Jun/2025
Roche Holding CHF 4.39B 1.04B Dec/2024
TG Therapeutics USD 34.84M 26.22M Jun/2025
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025